- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04726969
Efficacy and Safety of MOX/ALB Co-administration
Efficacy and Safety of Combination Moxidectin and Albendazole, Ivermectin and Albendazole and Albendazole Alone in Adolescents and Adults Infected With Trichuris Trichiura: a Randomized Controlled Trial
This study is a double-blind randomized controlled superiority trial aiming at providing evidence on the efficacy and safety of co-administered moxidectin and albendazole versus albendazole monotherapy (standard of care) against whipworm (T. trichiura) infections in adolescents and adults (12-60 years) in Côte d'Ivoire. One arm of patients will be treated with albendazole-ivermectin.
As measure of efficacy of the treatment the cure rate (percentage of egg-positive subjects at baseline who become egg-negative after treatment) will be determined 14-21 days post-treatment.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a double-blind randomized clinical trial which aims at providing evidence on the efficacy and safety of co-administered moxidectin and albendazole versus albendazole monotherapy (standard of care) against T. trichiura infections in adolescents and adults (12-60 years) in Côte d'Ivoire. Additionally, this study aims to substantiate evidence on the efficacy and safety of co-administered ivermectin and albendazole compared to albendazole monotherapy against T. trichiura in the same age group.
The primary objective of the trial is to comparatively assess the efficacy in terms of cure rate (CR) against T. trichiura infections among adolescents and adults (aged 12 to 60 years) of moxidectin/albendazole combination therapy and albendazole monotherapy.
The secondary objectives of the trial are to compare the egg reduction rates (ERR) of these treatment regimens (moxidectin/albendazole combination therapy vs. albendazole monotherapy) against T. trichiura, to assess the CRs and ERRs in T. trichiura-infected participants given ivermectin/albendazole combination therapy compared to those given albendazole monotherapy, to determine the CRs and ERRs of the drugs in study participants co-infected with A. lumbricoides and hookworm, and to evaluate the safety and tolerability of the treatment regimens. In addition, this study aims to characterize population pharmacokinetics and drug-drug interactions of the study drugs albendazole and ivermectin in T. trichiura infected adolescents (aged 12 to 20 years), to evaluate pharmacogenomics of ivermectin using whole genome sequencing, and to assess the effect of the gut microbiota on pharmacokinetics parameters and treatment outcome (CRs and ERRs), and drug-specific off-target effects of anthelmintic treatment on gut microbial communities in post-treatment samples.
After obtaining informed consent from individual/parents and/or caregivers, the medical history of the participants will be assessed with a standardized questionnaire, in addition to a clinical examination carried out by the study physician before treatment. Enrollment will be based on two stool samples, which will be collected, if possible, on two consecutive days or otherwise within a maximum of 5 days. All stool samples will be examined with duplicated Kato-Katz thick smears by experienced laboratory technicians.
Randomization of participants into the three treatment arms will be stratified according to intensity of infection. All participants will be interviewed before treatment, 3 and 24 hours and 14-21 days after treatment about the occurrence of adverse events. The efficacy of the treatment will be determined 14-21 days post-treatment by collecting another two stool samples.
The primary analysis will include all participants with primary end point data (available case analysis). Supplementary, a per-protocol analysis will be conducted. CRs will be calculated as the percentage of egg-positive subjects at baseline who become egg-negative after treatment. Differences among CRs between treatment arms will be analysed using crude and adjusted logistic regression modeling (adjustment for age, sex and weight).
Geometric and arithmetic mean egg counts will be calculated for the different treatment arms before and after treatment to assess the corresponding ERRs.
Bootstrap resampling method with 5,000 replicates will be used to calculate 95% confidence intervals (CIs) for differences in ERRs.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Abidjan, Côte D'Ivoire
- Centre Suisse de Recherches Scientifiques en Côte d'Ivoire (CSRS)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged between 12 and 60 years
- Written informed consent signed by either parents/caregivers for underage adolescents (aged 12-17 years) or by the participant him/herself (18-60 years of age); and written assent by underage participant
- Agree to comply with study procedures, including provision of two stool samples at the beginning (baseline) and at follow-up assessment 14-21 days after treatment
- Willing to be examined by a study physician prior to treatment
- At least two slides of the quadruple Kato-Katz thick smears positive for T. trichiura and infection intensities of at least 48 EPG
Exclusion Criteria:
- Presence or signs of major systemic illnesses, e.g. body temperature ≥ 38°C, severe anemia (below 80g/l Hb according to WHO) upon initial clinical assessment
- Known or suspected infection with Loa loa
- History of acute or severe chronic disease
- Abnormal liver function assessed by multiple biochemical blood-based analyses
- Recent use of anthelmintic drug (within past 4 weeks)
- Attending other clinical trials during the study
- Pregnancy, lactating, and/or planning to become pregnant within the next 3 months
- Known allergy to study medications (i.e. albendazole, ivermectin or moxidectin)
- Taking medication with known contraindication to or interaction with study drugs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A: moxidectin and albendazole
Combination therapy of moxidectin (8 mg, i.e. 4 tablets of 2 mg) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
|
Tablets of 2 mg moxidectin
Tablets of 400 mg albendazole
Other Names:
|
Placebo Comparator: Arm B: albendazole
Placebo (for moxidectin, 4 tablets) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
|
Tablets of 400 mg albendazole
Other Names:
|
Experimental: Arm C: ivermectin and albendazole
Combination therapy of ivermectin (Stromectol®, 200 µg/kg using tablets of 3 mg) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
|
Tablets of 400 mg albendazole
Other Names:
Tablets of 3 mg ivermectin
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cure Rate (CR) of Moxidectin/Albendazole Combination Therapy Compared to Albendazole Monotherapy Against T. Trichiura
Time Frame: 14-21 days after treatment
|
The CR will be calculated as the proportion of participants converting from being egg positive pre-treatment to egg negative post-treatment, multiplied by 100.
|
14-21 days after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Egg Reduction Rate (ERR) of Moxidectin/Albendazole Combination Therapy Compared to Albendazole Monotherapy Against T. Trichiura
Time Frame: 14-21 days after treatment
|
Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six.
Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment to assess the corresponding ERRs.
|
14-21 days after treatment
|
Cure Rate (CR) of Ivermectin/Albendazole Combination Therapy Compared to Albendazole Monotherapy Against T. Trichiura
Time Frame: 14-21 days after treatment
|
The CR will be calculated as the proportion of participants converting from being egg positive pre-treatment to egg negative post-treatment, multiplied by 100.
|
14-21 days after treatment
|
Egg Reduction Rate (ERR) of Ivermectin/Albendazole Combination Therapy Compared to Albendazole Monotherapy Against T. Trichiura
Time Frame: 14-21 days after treatment
|
Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six.
Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment to assess the corresponding ERRs.
|
14-21 days after treatment
|
Cure Rates (CRs) of the Study Drugs Against Ascaris Lumbricoides Infections in Co-infected Participants
Time Frame: 14-21 days after treatment
|
The CR will be calculated as the proportion of participants converting from being egg positive pre-treatment to egg negative post-treatment, multiplied by 100.
|
14-21 days after treatment
|
Egg Reduction Rates (ERRs) of the Study Drugs Against Ascaris Lumbricoides Infections in Co-infected Participants
Time Frame: 14-21 days after treatment
|
Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six.
Geometric and arithmetic mean egg counts will be calculated for the three treatment arms before and after treatment to assess the corresponding ERRs.
|
14-21 days after treatment
|
Cure Rates (CRs) of the Study Drugs Against Hookworm Infections in Co-infected Participants
Time Frame: 14-21 days after treatment
|
The CR will be calculated as the proportion of participants converting from being egg positive pre-treatment to egg negative post-treatment, multiplied by 100.
|
14-21 days after treatment
|
Egg Reduction Rates (ERRs) of the Study Drugs Against Hookworm Infections in Co-infected Participants
Time Frame: 14-21 days after treatment
|
Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six.
Geometric and arithmetic mean egg counts will be calculated for the three treatment arms before and after treatment to assess the corresponding ERRs.
|
14-21 days after treatment
|
Number of Participants Reporting Adverse Events (AEs)
Time Frame: 3 hours, 24 hours and 14-21 days after treatment
|
Participants will be monitored at the site for 3 hours following treatment for any acute AEs and reassessment will be done at 24h post-treatment.
In addition, participants will be interviewed 3 and 24 hours after treatment and retrospectively at days 14-21 about the occurrence of AEs.
|
3 hours, 24 hours and 14-21 days after treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Concentrations of Albendazole and Ivermectin/Albendazole Combination in Adolescents (Aged 12 to 20 Years)
Time Frame: 0 to 24 hours after treatment
|
For characterization of population pharmacokinetics (PK) and drug-drug interaction parameters ivermectin, albendazole and its metabolites will be quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method.
Drug concentrations will be calculated by interpolation from a calibration curve with a lower limit of quantification of 1-5 ng/ml.
|
0 to 24 hours after treatment
|
Genetic Variants in Ivermectin/Albendazole Participants
Time Frame: before treatment, i.e. at enrolment
|
In case of unexpected results for outcome measure 10 (Concentrations of Albendazole and Ivermectin/Albendazole Combination in Adolescents (Aged 12 to 20 Years)), whole genome sequencing will be performed on blood samples from participants in the ivermectin/albendazole arm to analyse genetic variation of relevance for ivermectin metabolism.
|
before treatment, i.e. at enrolment
|
Gut Bacterial Communities in Stool Samples
Time Frame: before treatment, i.e. at screening, and 14-21 days after treatment
|
Taxonomic relative abundances of gut bacterial communities will be analysed with high-throughput sequencing.
Absolute abundances of specific taxa will be measured using taxon-specific qPCR.
Changes in relative and absolute abundances will be measured before and after treatment.
|
before treatment, i.e. at screening, and 14-21 days after treatment
|
Exploratory Outcome: Number of Participants Within Each Blood Type Category (A, B, AB and 0)
Time Frame: before treatment, i.e. at enrolment
|
Blood type of participants will be collected during clinical examination prior treatment using blood type determination cards.
|
before treatment, i.e. at enrolment
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Parasitic Diseases
- Secernentea Infections
- Nematode Infections
- Helminthiasis
- Strongylida Infections
- Enoplida Infections
- Adenophorea Infections
- Ascaridida Infections
- Hookworm Infections
- Ancylostomiasis
- Trichuriasis
- Ascariasis
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antiprotozoal Agents
- Antiparasitic Agents
- Antinematodal Agents
- Anthelmintics
- Antiplatyhelmintic Agents
- Anticestodal Agents
- Ivermectin
- Moxidectin
- Albendazole
Other Study ID Numbers
- MAC_CI_1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hookworm Infections
-
Baylor College of MedicineJohns Hopkins University; University of California, San Francisco; George Washington... and other collaboratorsCompletedHookworm Infection | Hookworm DiseaseBrazil
-
Baylor College of MedicineCompletedHookworm Infection | Hookworm DiseaseGabon
-
Baylor College of MedicineGeorge Washington University; Amsterdam Institute for Global Health and Development and other collaboratorsCompletedHookworm Infection | Hookworm DiseaseGabon
-
Baylor College of MedicineCompletedHookworm Infection | Hookworm DiseaseBrazil
-
Baylor College of MedicineGeorge Washington University; Children's National Research InstituteCompletedHookworm Infection | Hookworm DiseaseUnited States
-
Jennifer KeiserPublic Health Laboratory Ivo de CarneriCompletedHookworm InfectionsTanzania
-
Albert B. Sabin Vaccine InstituteLondon School of Hygiene and Tropical Medicine; George Washington University; Oswaldo Cruz FoundationTerminatedHookworm InfectionBrazil
-
Baylor College of MedicineGeorge Washington UniversityCompletedHookworm Infection | Hookworm DiseaseUnited States
-
Baylor College of MedicineCompletedHookworm Infection | Hookworm DiseaseGabon
-
Baylor College of MedicineGeorge Washington UniversityCompletedHookworm Infection | Hookworm DiseaseUnited States
Clinical Trials on Moxidectin 2 mg Oral Tablet
-
Center for Research on Filariasis and Other Tropical...Active, not recruitingOnchocerciasis, Ocular | LoiasisCameroon
-
Jennifer KeiserPublic Health Laboratory Ivo de CarneriNot yet recruitingHookworm Infections | Ascariasis | TrichuriasisTanzania
-
Medicines Development for Global HealthWorld Health OrganizationCompleted
-
Cara Therapeutics, Inc.CompletedChronic Kidney Diseases | PruritusUnited States
-
Jennifer KeiserNational Centre for Parasitology, Entomology and Malaria Control, CambodiaCompletedStrongyloides Stercoralis InfectionCambodia
-
Swiss Tropical & Public Health InstitutePublic Health Laboratory Ivo de CarneriCompletedTrichuris Trichiura; InfectionTanzania
-
Zydus Therapeutics Inc.CompletedPrimary Biliary CirrhosisUnited States
-
Cassava Sciences, Inc.National Institute on Aging (NIA)Completed
-
Fulcrum TherapeuticsCompletedHealthy Adult SubjectsUnited States
-
Jennifer KeiserPublic Health Laboratory Ivo de CarneriCompletedHookworm Infections | Helminthes; Infestation, Intestinal | Ascariasis | TrichuriasisTanzania